PAPERZILLA
Crunching Academic Papers into Bite-sized Insights.
About
Sign Out
← Back to papers
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology
Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription
★
★
★
★
☆
SHARE
Overview
Paper Summary
Conflicts of Interest
Identified Weaknesses
Rating Explanation
Good to know
Topic Hierarchy
File Information
Paper Summary
Paperzilla title
Emodin: The Weed That Starves Tumors (in Mice, at Least)
This study found that emodin, a natural compound from Chinese herbs, inhibits tumor angiogenesis and growth in triple-negative breast cancer (TNBC) models by increasing the expression of SerRS, a transcriptional repressor of VEGFA. Emodin directly interacts with NCOR2, leading to its dissociation from the SerRS promoter and subsequent SerRS activation.
Possible Conflicts of Interest
None identified
Identified Weaknesses
Lack of human clinical data
The study primarily uses in vitro and in vivo models, lacking human clinical data to support the findings. Translational research is needed to confirm the efficacy and safety of emodin in human TNBC patients.
Poor pharmacokinetic properties of emodin
While emodin shows promising results in preclinical models, its poor pharmacokinetic properties, particularly low bioavailability, pose a significant challenge for clinical translation.
Multiple pharmacological activities of emodin
The study focuses on the anti-angiogenic effects of emodin, but its other pharmacological activities, such as cytotoxicity and induction of apoptosis, could confound the interpretation of the results. It's crucial to disentangle these effects to fully understand emodin's mechanism of action.
Incomplete mechanistic understanding
Although the study identifies NCOR2 as the direct target of emodin, further research is needed to fully elucidate the downstream signaling pathways and the precise mechanism by which emodin modulates NCOR2 activity.
Rating Explanation
This is a well-designed preclinical study with compelling in vitro and in vivo data supporting the anti-angiogenic and anti-tumor effects of emodin in TNBC models. The identification of NCOR2 as a direct target is a significant finding. However, the lack of human clinical data and the known pharmacokinetic limitations of emodin warrant a rating of 4 instead of 5.
Good to know
This is our free standard analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →
Topic Hierarchy
File Information
Original Title:
Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription
File Name:
pmc7295066.pdf
[download]
File Size:
2.54 MB
Uploaded:
July 14, 2025 at 11:27 AM
Privacy:
🌐 Public
© 2025 Paperzilla. All rights reserved.